CSL Limited makes many of its therapies from donated plasma, which posed a challenge as pandemic lockdowns led to a steep drop in plasma collections. In acquiring Vifor Pharma, CSL not only diversifies, it also expands its presence in the fast-growing nephrology market.
Talecris Biotherapeutics shareholders will spend Valentine's Day voting whether to approve the $3.4 billion offer from Spanish company Grifols to buy the company. But the merger faces a more important test. The Federal Trade Commission could still block the deal on antitrust grounds as it did two years ago when CSL Limited tried to buy Research Triangle Park-based Talecris.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.